Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
125I-HE3-G3
- Development stage
- Preclinical
- Lead developer
- University of Zurich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
125I-HE3-G3 is a radiolabeled designed ankyrin repeat protein (DARPin) developed for the in vivo molecular imaging of human epidermal growth factor receptor 2 (HER2) expression. It consists of the G3 DARPin, which binds with picomolar affinity to domain IV of the HER2 ectodomain, modified with an N-terminal histidine-glutamate (HE)3 tag to reduce non-specific background liver uptake, and radiolabeled with Iodine-125 (125I). Developed by researchers at University College London (UCL) Cancer Institute, Barts Cancer Institute, and the University of Zurich, 125I-HE3-G3 is designed to assess HER2 status in breast cancer and other HER2-positive malignancies, enabling non-invasive patient stratification and monitoring of treatment response.
- Other names
- 125I-(HE)3-G3125I-(HE)3-G3 DARPin125I-HE3-G3 DARPin125I-labeled (HE)3-G3 DARPin125I-labeled HE3-G3125I-labeled HE3-G3 DARPiniodine-125 HE3-G3iodine125 HE3-G3iodine 125 HE3-G3
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 125I-HE3-G3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 125I-HE3-G3.